REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

12/04/2019 16:35

RNS Number : 1078W
GlaxoSmithKline PLC
12 April 2019
 


GlaxoSmithKline plc (the 'Company')
Transaction notification




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mrs V A Whyte




b)


Position/status


Company Secretary




c)


Initial notification/
amendment              


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.7335


35




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-11




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I W Whyte




b)


Position/status


PCA of Mrs V A Whyte (Company Secretary)




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.  




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.7335


880




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-11




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mrs D Connor




b)


Position/status


PCA of Mr R G Connor (President, Global Vaccines)




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.  




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.7335


645




  
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-11




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHELLFFKZFXBBF